STAA · Staar Surgical Co
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY27 earnings call · Aug 12, 2026TL;DR. STAAR reported Q2 2026 net sales of $93.5 million, up 111% year-over-year, swung to net income of $8.1 million, and lifted cash to $181.5 million with no debt, driven by EVO+ adoption and sequential China share gains; management also flagged that Q3 2025 included a $25.9M one-time order that distorts year-over-year comparisons.
- + China sales grew over 100% Y/Y to $52.3M, 10% sequentially, fueled by EVO+ adoption and share gains
- + Gross margin expanded to 74.5% from 74.0%, reflecting Switzerland ramp benefit and lower manufacturing expenses
- + Americas grew 12% Y/Y with a second consecutive quarter above $6M in U.S. net sales
- + R&D pipeline advancing toward first-in-human studies on next-generation products with a new CTO being hired
- − Gross margin was negatively impacted by China tariffs on U.S.-manufactured product, expected to persist until end of 2026
- − EMEA reported sales declined 1% Y/Y due to Middle East conflicts
- − Q3 2026 year-over-year comparison is distorted by a $25.9M one-time 2024 order that will not repeat
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STAA
this stock
Staar Surgical Co
|
$1.18B | +1.6% | -23.7% | 294.7 | 8.8% |
|
ISRG
Intuitive Surgical Inc
|
$130.62B | -35.3% | +20.5% | 42.5 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$50.32B | — | +8.2% | — | 3.4% |
|
MDLN
Medline Inc.
|
$48.24B | -12.9% | +11.5% | — | 2.8% |
|
ALC
Alcon Inc
|
$34.27B | -10.5% | +10.5% | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STAA | +6.2% | -3.1% | +29.8% | +3.9% | +1.7% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +6.0% | -2.7% | +14.7% | +3.5% | -11.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.